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Abstract
Stroma properties affect carcinoma physiology and direct malignant cell development. Here we present data showing that
aVb3 expressed by stromal cells is involved in the control of interstitial fluid pressure (IFP), extracellular volume (ECV) and
collagen scaffold architecture in experimental murine carcinoma. IFP was elevated and ECV lowered in syngeneic CT26
colon and LM3 mammary carcinomas grown in integrin b3-deficient compared to wild-type BALB/c mice. Integrin b3-
deficiency had no effect on carcinoma growth rate or on vascular morphology and function. Analyses by electron
microscopy of carcinomas from integrin b3-deficient mice revealed a coarser and denser collagen network compared to
carcinomas in wild-type littermates. Collagen fibers were built from heterogeneous and thicker collagen fibrils in carcinomas
from integrin b3-deficient mice. The fibrotic extracellular matrix (ECM) did not correlate with increased macrophage
infiltration in integrin b3-deficient mice bearing CT26 tumors, indicating that the fibrotic phenotype was not mediated by
increased inflammation. In conclusion, we report that integrin b3-deficiency in tumor stroma led to an elevated IFP and
lowered ECV that correlated with a more fibrotic ECM, underlining the role of the collagen network for carcinoma
physiology.
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Introduction
In addition to the malignant cells a carcinoma contains a
connective tissue compartment, or stroma, which constitutes the
microenvironment for the malignant cells. Malignant cells must
initiate or alternatively find a permissive microenvironment in
order to establish themselves and grow. The microenvironment
extracellular matrix (ECM) provides a scaffold for tumor growth
and blood supply. The stroma typically exhibits distorted blood
vessels, hypoxia, and acidic pH, as well as infiltrating myeloid cells
and activated connective tissue cells that commonly produce a
fibrotic ECM [1–4]. Formation of a stroma depends on signals
from the malignant carcinoma cells and the non-malignant
vascular, connective tissue and inflammatory cells. The stroma
in turn influences the phenotype of the malignant cells [2–4].
Several experimental studies have pointed to the expression of
collagen type I in the microenvironment and degree of cross-
linking of collagen fibers as a determining factor in tumor
progression including metastasis [4–6].
Interstitial fluid pressure (IFP) is one of the Starling forces [7]
that control capillary-to-interstitium fluid transport. In normal
loose interstitial connective tissue, the IFP is close to zero, or
slightly negative, and will normally limit perturbations in fluid
exchange. However, during anaphylaxis, inflammation and burn
injuries, the properties of the loose connective tissue surrounding
blood vessels is altered, reflected by a rapid reduction in IFP that
induces, rather than prevents increases in extracellular volume
(ECV) and subsequent edema formation [8]. Available data
suggest that connective tissue cells apply tensile forces on ECM
fibers, which, in turn, inhibit the under-hydrated ground substance
from taking up fluid and swell. A decrease in cellular tension on
the ECM fibers allows the ground substance to swell, i.e. to form
edema. b1-integrins mediate the tensile forces from the cytoskel-
eton to the ECM in normal tissues. However, dermal IFP lowered
after anaphylaxis can be normalized by instilments of PDGF-BB
or insulin [9–11] by a mechanism dependent on integrin aVb3
instead of b1-integrins [12,13]. Carcinomas are characterized by a
pathologically high IFP, which leads to impaired uptake of anti-
cancer drugs into the carcinoma [14–16]. Agents that lower IFP in
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e34082experimental carcinoma, increase the uptake and efficacy of
chemotherapeutic agents [17–20].
Inhibition of PDGF-B with an aptamer that specifically binds
and immobilizes PDGF-B or, alternatively, inhibition of PDGF
receptors with the selective tyrosine kinase inhibitor STI571
(Glivec/Imatinib), lowers IFP in experimental carcinoma. This has
been shown to increase both capillary-to-interstitium transport of a
low-molecular weight tracer and sensitivity to chemotherapeutic
agents [21]. As aVb3 is activated downstream of stimulation by
PDGF-BB or insulin during IFP regulation in dermis [12,13], we
reasoned that an investigation into whether integrin aVb3 is crucial
for elevated IFP in tumors was warranted. Here, we have
investigated properties of the stroma in carcinomas grown in
mice lacking the integrin b3-subunit to test if the absence of
integrin aVb3 signaling results in lowered IFP.
Results
The lack of integrin b3-subunit in stroma elevates
interstitial fluid pressure in experimental carcinoma
CT26 colon carcinoma and LM3 breast carcinoma cells formed
tumors in integrin b3-deficient and WT mice with a 100% tumor
take in both genotypes. LM3 breast carcinomas were grown in
female mice, whereas CT26 carcinomas were grown at equal
ratios in male and female mice. Tumor end-weights showed no
significant difference in integrin b3-deficient compared to WT
mice in either CT26 tumors or LM3 tumors (Figure S1A & B).
The IFP in both CT26 and LM3 carcinomas was, however,
significantly higher in b3-deficient carcinomas (Figure 1A and 1B).
CT26 carcinomas had an average IFP of 4.260.3 mmHg when
grown in integrin b3-deficient mice (n=21) and 2.660.2 mmHg
(p,0.001) when grown in WT mice (n=24). The corresponding
values for LM3 carcinomas were 6.160.8 and 2.960.4 mmHg
(n=6 for each genotype; p,0.05), respectively.
The lack of integrin b3-subunit in stroma alters collagen
architecture in experimental carcinoma
Ultrastructural analyses of the collagen scaffold by scanning
electron microscopy (EM) at high magnification (610,000)
revealed striking differences in collagen fiber structure between
carcinomas grown in b3-deficient and WT mice. In b3-deficient
mice, both CT26 and LM3 carcinomas displayed a mixture of thin
and thicker abnormally fused collagen fiber bundles whereas these
features were limited in the WT counterparts (Figure 2A).
Analyses of collagen fibril structure by transmission EM
revealed a heterogeneous distribution with laterally fused,
cauliflower shaped fibrils in carcinomas grown in integrin b3-
deficient mice (Figure 2B, white arrowheads) with significantly
larger size compared to tumors grown in WT mice. To study the
fibril diameter distribution for the total number of fibrils counted
on the micrographs from CT26 tumors grown in integrin b3-
deficient mice (n=2159) and WT mice (n=2043), each value for
the fibril diameter (data point) were plotted in a histogram
(Figure 2B). The fibril distribution in CT26 tumors from integrin
b3-deficient mice was 57 nm in the 25
th percentile and 99 nm in
the 75
th percentile, while it was 37 nm in the 25
th percentile and
50 nm in the 75
th percentile for the fibrils in tumors grown in
WT mice. Hence, the histogram confirmed the uneven
distribution of fibril diameters revealing a clear shift to thicker
fibrils. Further analyses showed a significant increase (p,0.03) in
the average fibril diameter in CT26 carcinomas grown in
integrin b3-deficient mice (79613 nm) compared to WT mice
(4462 nm) (n=5 for each genotype; Figure S2A). The same
analyses on the micrographs from LM3 tumors grown in integrin
b3-deficient mice (n=1286) and WT mice (n=791) for each
fibril counted also showed a clear shift to thicker fibrils in LM3
tumors from integrin b3-deficient mice with a fibrils distribution
of 49 nm in the 25
th percentile and 62 nm in the 75
th percentile,
while it was 41 nm in the 25
th percentile and 53 nm in the 75
th
percentile for the fibrils in tumors grown in WT mice (Figure 2B).
In addition, a significant increase (p,0.05) was found in the
average fibril diameter in LM3 carcinomas grown in integrin b3-
deficient mice (5662 nm) compared to WT mice (4762n m )
(n=3 for each genotype; Figure S2B). In contrast, ultrastructural
analyses of tail tendons, dermis and Achilles tendons showed no
differences in collagen fibrils between the genotypes (Figure 2C
and data not shown). No significant difference could be observed
in collagen fibril distribution from tail dermis derived from b3-
deficient (n=1157) or WT mice (n=1715) (Figure 2C) or in
average fibril diameter in b3-deficient (8167n m ) a n d W T
dermis (8166 nm) (n=2 for each genotype; p.0.98; Figure
S2C).
Increased collagen fiber thickness and fibril diameter in tumors
from integrin b3-deficient mice could be an indicator of elevated
production of collagen. Indeed, there was a trend towards
increased mRNA transcription levels of the fibrillar pro-collagen
chains for Col1a1 and Col5a2, and a significant increase in Col3a1
in integrin b3-deficient CT26 tumors (p,0.05) when compared to
CT26 tumors grown in WT mice (Figure 3A) as determined by
quantitative real-time PCR (qRT-PCR). In addition, elevated
expression of the collagen cross-linking enzyme lysyl oxidase (Lox)
was detected in integrin b3-deficient CT26 tumors (Figure 3A). A
similar increase in fibrillar pro-collagens and Lox mRNA levels
were observed in LM3 tumors grown in integrin b3-deficient mice
when compared to LM3 tumors grown in WT mice (Figure S3).
Analyses of collagen content in CT26 carcinomas by hydroxy-
proline quantification showed a trend towards a higher collagen
content in carcinomas grown in integrin b3-deficient compared to
WT mice (Figure 3B).
The increased production of collagen and the abnormal fusion
of the collagen fibrils and fibers could also indicate an altered
activity of collagenase enzymes. Although decreased mRNA
levels of matrix metalloproteinases (Mmp) 28a n d213 were
observed in CT26 carcinomas from integrin b3-deficient
compared to WT mice (Figure 3C), there was no significant
difference in tumor collagenase activity between the two
genotypes (Figure 3D).
Figure 1. Interstitial fluid pressure (IFP) in CT26 and LM3
carcinomas. A) CT26 carcinomas. Data are from combined experi-
mental series (n=24 for WT; n=21 for integrin b3-deficient mice).
** indicates p,0.001 by Student’s t-test. Error bars are SEM. B) LM3
carcinomas. Data are from one experiment (n=6 per genotype).
* indicate p,0.05 by Mann-Whitney test. Error bars are SEM.
doi:10.1371/journal.pone.0034082.g001
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PLoS ONE | www.plosone.org 3 March 2012 | Volume 7 | Issue 3 | e34082Figure 2. Analyses of collagen scaffold structure in CT26 and LM3 carcinomas grown in WT and integrin b3-deficient mice. A)
Representative scanning electron micrographs at 610,000 magnification revealed thicker, fused collagen fibers in both CT26 tumors (n=5 per
genotype) and LM3 tumors (n=3 per genotype) grown in integrin b3-deficient mice (bars=5 mm). B) Ultrastructural analysis of CT26 tumors (n=5
per genotype) and LM3 tumors (n=3 per genotype). Representative transmission electron micrographs on collagen fibril morphology demonstrated
a heterogeneous fibril diameter distribution in CT26 tumors and LM3 tumors (at615,500 and611,500 magnification, respectively) grown in integrin
b3-deficient compared to WT mice. Some of the fibrils were laterally fused (white arrowheads) in tumors grown in b3-deficient mice (bars=500 nm).
Histogram on collagen fibril distribution in CT26 tumors grown in integrin b3-deficient (black bars; n=2159) and WT mice (white bars; n=2043) and
in LM3 tumors from integrin b3-deficient (black bars; n=1286) and WT mice (white bars; n=791), showing a clear shift toward thicker fibrils in both
tumor types grown in integrin b3-deficient mice. C) Representative micrographs on tail dermis collagen fibrils from WT and integrin b3-deficient mice
showed similar fibril distribution between the two genotypes (n=2; bar=500 nm). No significant difference could be observed in collagen fibril
distribution from tail dermis derived from b3-deficient (black bars; n=1157) or WT mice (white bars; n=1715). To analyze fibril distribution, each data
point (diameter for each fibril) was tabulated in GraphPad using the Frequency distribution analysis tool.
doi:10.1371/journal.pone.0034082.g002
Figure 3. Quantitative RT-PCR analysis, hydroxyproline measurements and assay for MMP-13 activity. A) Relative mRNA expression of
fibrillar pro-collagens and lysyl oxidase (Lox) in CT26 carcinomas from integrin b3-deficient (n=12) compared to WT mice (n=11). Bars indicate fold
changes in tumors from b3-deficient mice after normalization to tumors from WT mice using the 2
2DDCt method. * indicates p,0.05 with Student’s t-
test. Error bars are SEM. B) Hydroxyproline content in CT26 carcinomas grown in integrin b3-deficient and WT mice (n=4 per genotype). Data was
analyzed with Student’s t-test. Error bars are SEM. Differences in collagen content were not significant. C) Fold change in relative mRNA expression
for the collagenases Mmp8 and Mmp13 in CT26 carcinomas from integrin b3-deficient (n=12) compared to WT mice (n=11). D) CT26 tumor
homogenates of each genotype were subjected to a MMP assay (n=6). Recombinant MMP-13 and samples were activated by 4-
aminophenylmercuric acetate for 40 min at 37uC. Fluorescence resulting from the cleavage of the substrate 5-FAM/QXL
TM520 FRET peptide was
measured. Data was analyzed with Student’s t-test. Error bars are SD.
doi:10.1371/journal.pone.0034082.g003
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vascular density, pericyte coverage or blood vessel
function
CD31 immunostaining showed an abundance of vessels in the
viable zone of CT26 carcinomas grown in both integrin b3-
deficient and WT mice but no significant differences in vessel
density and morphology as assessed by stereology (Figure 4). Also,
qRT-PCR analyses of mRNA expression from integrin b3-
deficient and WT tumors showed equal levels of VEGF
receptor-2 transcripts (Figure S4). Antibodies to the chondroitin
sulfate proteoglycan NG2 were used to visualize activated
pericytes. NG2 is known to be selectively expressed by pericytes
in the vasculature of tumors [22]. Blood vessels in carcinomas
grown in integrin b3-deficient mice displayed reduced NG2
positive staining and less co-localization between NG2 and CD31
(Figure 5A–C), but there were no significant difference in vascular
coverage by a-SMA staining (Figure 5B and 5C). Hence, the
pericyte coverage were similar between CT26 carcinomas grown
in integrin b3-deficient and WT mice, however the phenotype of
the pericytes differed between these two conditions. Additionally,
a-SMA staining was not only confined to the vascular compart-
ment, since also the extravascular compartment of the tumor
stroma was positive for a-SMA staining (Figure 5C). There was no
difference in total a-SMA staining in tumors from b3-deficient or
WT mice (Figure 5A). Staining with reticular fibroblast marker
showed no difference between the genotypes (data not shown),
which supports equal content of carcinoma-associated fibroblasts.
Vascular leakage of plasma proteins as determined by the modified
Miles’ assay, was similar in CT26 carcinomas grown in integrin
b3-deficient and WT mice (Figure 5D). Moreover, the plasma
volumes (PV) in CT26 carcinomas in the two genotypes were not
significantly different, further supporting the hypothesis that
vascular function was not affected by integrin b3-deficiency
(Table 1). The extracellular volume (ECV) was, however,
significantly lower in carcinomas grown in integrin b3-deficient
mice (p,0.04), whereas total tissue water (TTW) was similar
(Table 1). Collectively, the data show that the lack of integrin b3-
subunit in tumor stroma has little effect on vascular function in
CT26 carcinoma.
Reduced amounts of macrophages and inflammatory
cytokines in tumors from integrin b3-deficient mice
The numbers of F4/80 positive macrophages were significantly
lower in CT26 carcinomas grown in integrin b3-deficient mice
compared to tumors from WT animals (Figure 6A). However,
there was no significant difference in the fraction of F4/80 staining
that co-localized with MHC Class II staining (data not shown),
which indicates that there was no difference in the fraction of
macrophages with an activated phenotype. In close agreement
with these results, qRT-PCR analysis indicated a down-regulation
of pro-inflammatory transcripts in CT26 carcinomas grown in
integrin b3-deficient compared to WT mice (Figure 6B), with
significant decrease in S100A9, interleukin 1b (IL-1b), interferon-c
(Ifn-c) and osteopontin (Opn) expression. However, there was no
difference in MHC II mRNA expression.
Discussion
We present data showing that absence of the integrin b3-subunit
in the stroma of transplanted syngeneic LM3 mammary and
CT26 colonic carcinomas results in a denser and coarser collagen
network composed of thicker and irregular collagen fibrils. These
qualitative changes in the collagen network architecture were
paralleled by an elevated IFP. The present study thus support the
hypothesis that IFP in carcinoma depend on qualitative properties
of the stroma collagen network. We furthermore demonstrate that
integrin b3-deficiency had no effect on the collagen scaffold
architecture in dermis or tendons. The data advocate that b3-
integrins have a role in determining collagen scaffold architecture
in response to growth of malignant cells but are not involved in the
buildup of normal connective tissue.
We have previously reported that PDGF-BB normalizes dermal
IFP that has been reduced as a result of anaphylaxis and that this
process critically depends on integrin aVb3 [23]. The control of
IFP in vivo shares characteristics with collagen gel contraction in
vitro and has been suggested to rely on modulation of tensile forces
exerted by connective tissue cells on the ECM (reviewed in [8]).
Furthermore, inhibition of PDGF-BB or PDGF-receptors lowers
IFP in experimental carcinoma [18,21]. This led us to hypothesize
that carcinomas grown in integrin b3-deficient mice might have a
reduced IFP compared to carcinomas grown in WT mice.
However, the present data support a quite opposite conclusion,
namely that in carcinoma, integrin aVb3 is not only dispensable for
maintaining an elevated IFP but rather participates in processes
that counteract increases in IFP. In this context it is worth noting
that whereas PDGF BB-stimulated normalization of IFP in loose
connective tissues occurs within minutes, reduction of carcinoma
IFP by PDGF inhibitors requires days and is compatible with an
effect on stroma architecture. A maintained high IFP in the tumor
as observed here must mean that the hydraulic conductivity in the
tumor interstitium is low providing a flow resistance to the
drainage of fluid from the tumor interstitium towards the part of
Figure 4. Quantitative analyses of vascular parameters.
Stereology of CD31-positive vessels in CT26 carcinomas grown in
integrin b3-deficient (n=9) and WT mice (n=6). 6 mm sections stained
for CD31 by immunohistochemistry were counted,6200 magnification.
Data was analyzed with Student’s t-test. Error bars are SEM.
doi:10.1371/journal.pone.0034082.g004
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remove the interstitial fluid.
Reduction of carcinoma IFP increases uptake and efficacy of
low molecular weight cytostatic drugs in experimental carcinoma
[17–19,21,24]. Inhibition of TGF-b1 and -b3 in xenograft
carcinomas reduce IFP as well as the density of the collagen
network in the tumors [25] and increases efficacy of cytostatic
treatment [20]. Reduction of tumor fibrosis in a transgenic mouse
model of pancreatic cancer has the same effect as lowering IFP on
the uptake and efficacy of chemotherapeutics [26]. Furthermore,
inhibition of collagen type I synthesis and deposition in
experimental carcinoma, by treatment with losartan increase
efficacy of nanotherapeutics [27]. Previous studies thus suggest
that modulations of the collagen scaffold in carcinoma may be an
effective way to increase efficacy of chemotherapy. Our present
data opens for the possibility that functional down-regulation of
integrin aVb3 could render carcinoma less accessible for
chemotherapy by making the collagen scaffold less permissive for
transport of solutes through the tumor tissue.
The relevance of the integrin aVb3 in tumor angiogenesis is
uncertain [28,29]. Mice lacking integrin b3 have been reported to
support effective angiogenesis [30,31] whereas pharmacological
inhibition of aVb3 reduces angiogenesis in certain models [32].
The present data are consistent with reports showing that integrin
aVb3 is not needed for tumor angiogenesis in that b3-deficiency
had no significant effects on vessel density or morphology.
Furthermore, integrin b3-deficiency had no significant effect on
levels of mRNA encoding VEGF receptor-2. However, we
recorded a difference in content and coverage of blood vessels
by NG2-positive pericytes. On the other hand, a-SMA staining of
vascular structures was similar between the two genotypes,
indicating that there was no difference in pericyte coverage. The
observed reduction in expression of NG2 by pericytes in b3
integrin-deficient tumors did not affect vascular density, plasma
protein leakage or plasma volume. Together our results point to
that the increased IFP in integrin b3-deficient tumors could not be
attributed to any of the vascular parameters studied.
Differences in the vascular phenotype acquired by inhibition of
VEGF receptor-2 or VEGF-A reduces IFP in experimental
carcinoma [33,34]. VEGF inhibition in KAT-4 carcinoma results
in reductions of plasma protein leakage and ECV in parallel with a
reduction of IFP [34]. In the present study, we observed that
vascular leakage, a surrogate marker for vascular function, was not
affected by the absence of integrin b3 in CT26 carcinomas,
whereas ECV decreased and IFP increased. When taken together,
available data counter the notion of a direct correlation between
plasma protein leakage on the one hand, and ECV and IFP on the
other. Treatment of experimental carcinoma with an inhibitor of
PDGF receptors [35], with prostaglandin E1 [19] or growth of
carcinoma in fibromodulin-deficient mice [25] generate tumors
that have an increased ECV and reduced IFP. Our present data
show that ECV was decreased and IFP increased in CT26
carcinomas grown in integrin b3-deficient animals, which fits with
the aforementioned relation between ECV and IFP. If, however,
plasma protein leakage is changed, as it appears to do after
inhibition of the VEGF system [33,34], this relation between ECV
and IFP is not evident [34].
It has been reported that TGF-b signaling is enhanced during
wound healing in integrin b3-deficient mice [36]. The increase in
collagen deposition and network density reported here could have
been due to an up-regulation of TGF-b signaling in CT26
carcinomas grown in b3-deficient mice. However, we did not
detect any significant changes in mRNAs encoding TGF-b1,
TGF-b3, TGFbR-II or connective tissue growth factor (CTGF) in
CT26 carcinomas grown in integrin b3-deficient mice (Figure S4).
CTGF expression reportedly is down-stream of TGF-b induced
signaling [37] suggesting that the lack of stromal b3-integrin had
little effect on TGF-b activation. Collectively, our data suggest that
Figure 5. Pericyte coverage in CT26 carcinomas grown in
integrin b3-deficient and WT mice. A) The total fraction of pxl.
positive for NG2 or a-SMA were quantitated. B) The amount of CD31
and NG2 double positive pixels (pxl.) and CD31 and a-SMA double
positive pixels were quantitated and presented as the fraction of CD31
pixels that were also NG2 or a-SMA positive. C) Representative
immunofluorescence images of CD31 double stained with either NG2
or a-SMA in CT26 carcinoma sections from both genotypes (6 200
magnification). D) Leakage of Evans blue dye was assessed in integrin
b3-deficient (n=4) and WT mice (n=5) bearing CT26 carcinomas.
Leakage was corrected for the tumor plasma volume. Data are
presented as leaked volume plasma per tumor tissue dry weight. Bar
is 50 mm. * indicates p,0.05 and ** indicates p,0.01 by Mann-Whitney
test. Error bars are SEM.
doi:10.1371/journal.pone.0034082.g005
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integrin b3-deficiency are caused by an increased activity of TGF-
b.
The reduction in macrophage content in CT26 carcinomas
grown in integrin b3-deficient mice is consistent with earlier
reports showing reduced macrophage infiltration in healing
wounds [36] and experimental carcinoma [38] when integrin b3
is absent. The observed decrease in numbers of infiltrating
macrophages may explain the decreased transcription levels of
Mmp-8, Mmp-13 and Opn [39,40]. The decreased expression of
transcripts for the collagen degrading enzymes Mmp-8 and Mmp-
13 may indicate perturbed collagenase activity, possibly affecting
the architecture of the collagen scaffold in tumors. We were,
however, unable to detect any difference in extractable MMP
activity in lysates from b3-deficient and WT mice. Our data
challenge the concept of a direct correlation between the degree of
inflammation in carcinoma on the one hand and fibrosis on the
other. It is possible that such a correlation exists in wild-type mice
but that the absence of aVb3 decouples this relation. Further
studies are needed to evaluate the relation between inflammation
and fibrosis in carcinoma.
In conclusion, our data provide further support for a direct
relationship between fibrosis and elevated IFP in carcinoma.
Whether the increased fibrosis results from the disturbed fluid
balance and hypertension in the carcinoma or if the fibrosis
generates these disturbances in fluid maintenance in carcinoma is
not clear.
Materials and Methods
Ethics Statement
All animal experiments were approved by the ethical commit-
tees for animal experiments in Uppsala, Sweden (permit number:
C76/10) and in Bergen, Norway (permit number: 20102809).
Tumor models
The BALB/c syngeneic tumor cell lines LM3 mammary
carcinoma (kind gift of Dr. Elisa Bal de Kier Joffe ´, University of
Buenos Aires, Argentina) [41] and CT26 mouse colon carcinoma
(ATCC, Manassas, VA) were grown in RPMI 1640 (Invitrogen,
San Diego, CA) supplemented with 10% Fetal Bovine Sera
(Saveen-Werner, Limhamn, Sweden) and 60 mg/mL penicillin
and 50 mg/mL streptomycin (SVA, Uppsala, Sweden). Fifty mLo f
cell suspension containing either 1.5610
5 CT26 cells or 5610
5
LM3 cells were injected into the left flank of BALB/c wild type or
integrin b3-deficient mice [42]. The BALB/c integrin b3-deficient
mouse strain was a gift from Richard O. Hynes, MIT, MA, USA.
Integrin b3- deficient mice were bred heterozygous but prior to the
experiments b3-deficient and WT mice lines were segregated. The
mice were fed ad libitum and cared for regularly. CT26 tumors
were grown for 3–4 weeks and LM3 tumors were grown 3–5
weeks. Upon sacrifice, all tumors were weighed before further
analysis.
Interstitial fluid pressure (IFP) measurements
Mice with tumors ranging in size between 0.5 and 1.5 mL were
put on a heating pad under isofluran (Forene, Abbot Scandinavia,
Table 1. Plasma volume (PV), extra cellular volume (ECV) and total tissue water (TTW) measurements in CT26 carcinomas and
normal skin from integrin b3-deficient and WT mice.
PV ECV TTW
mL/g dry weight mL/g dry weight mL/g dry weight
Skin (WT) (n=5) 0.02960.007 0.77860.158 1.83660.995
Skin (b3KO) (n=5) 0.03960.018 0.64360.123 1.65760.331
Tumor (WT) (n=8) 0.07760.030 0.74060.125 3.97560.418
Tumor (b3KO) (n=8) 0.09460.051 0.47260.252* 3.93260.445
CT26 carcinomas (n=8 per genotype) and skin (n=5 per genotype).
*indicates p,0.04 between tumors from integrin b3-deficient and WT mice, determined with Student’s t-test. Values are 6 SEM.
doi:10.1371/journal.pone.0034082.t001
Figure 6. Inflammatory parameters in CT26 carcinomas. A)
Macrophage content in CT26 carcinomas. The fraction of F4/80 positive
pixels per image frame is presented (n=7 for each genotype, 6200
magnification). * indicates p,0.05 by Mann-Whitney test. Error bars are
SEM. B) QRT-PCR analysis of pro-inflammatory genes in CT26
carcinomas grown in integrin b3-deficient (n=12) compared to WT
mice (n=11). Bars indicate fold changes in tumors grown in integrin b3-
deficient mice after normalization to tumors from WT mice using the
2
2DDCt method. * indicates p,0.04; ** indicates p,0.01 with Student’s
t-test. Error bars are SEM.
doi:10.1371/journal.pone.0034082.g006
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in the-needle’’ technique using 23 G needle as described [24]. At
least three measurements were performed on every tumor. Four
separate experiments were performed with CT26 tumors grown in
integrin b3-deficient (n=21) and WT mice (n=24) and one with
LM3 tumors grown in integrin b3-deficient and WT mice (n=6
for each genotype). All mice were sex and aged matched in every
experiment.
Determination of plasma protein leakage in tumors
A modified Miles’ assay was used, where Evans blue dye (EBD,
100 mL, 30 mg/kg body weight, Sigma, St Louis, MO) dissolved
in 0.9% NaCl was injected i.v. into integrin b3-deficient (n=4) and
WT mice (n=5) bearing CT26 tumors. After 30 min, blood was
collected from the inferior vena cava and mice were subsequently
sacrificed. The tumors were dissected and three pieces from each
tumor was collected. The average piece weighed 3716158 mg.
The tumor pieces were dried in a vacuum centrifuge. The dried
tumor pieces were then incubated with 1 mL of formamide
(Sigma) at 55uC for 16 hours. The amount of EBD in tumors and
serum was quantified at 600 nm with a spectrophotometer
(Titertek, Huntsville, AL). Measurements of EBD leakage were
corrected for the tumor plasma volume (PV).
Extracellular volume, plasma volume and total tissue
water measurements
Extracellular volume (ECV) and plasma volume (PV) in CT26
tumors (n=8 for each genotype) and skin (n=5 for each genotype)
were determined by the dilution principle using radioactive-
labeled isotopes [34]. Total tissue water (TTW) was determined as
(wet weight-dry weight)/dry weight. Tissue samples were dried at
50uC for 3–4 weeks until the weight was constant. The distribution
volumes for
51Cr-EDTA (Institute of Energy Technology, Kjeller,
Norway) and
125I-labeled human serum albumin (
125I-HSA;
Institute of Energy Technology), measuring ECV and PV
respectively, were calculated as plasma equivalent volumes, i.e.
counts per min (cpm) per mg of tissue divided by counts per min
per mL of plasma. Both isotopes were given after functional
nephrectomy by bilateral ligation of the renal pedicles via flank
incision.
51Cr-EDTA (300,000 cpm in 0.2 mL PBS) was injected
into the catheter in the tail vein and left to circulate for 85 min
before injecting
125I-HSA (3610
6 cpm in 0.2 mL PBS). Blood
samples were taken 5 min later by heart puncture. Skin from the
back was used as a reference control. Radioactivity was
determined in a COBRA II, Auto-gamma counter (Packard,
Waltham, MA) with automatic background and spillover correc-
tion.
Immunohistochemistry and immunofluorescence
Upon sacrifice, CT26 tumors were dissected and snap frozen
in isopentane at 280uC. Frozen 6 mm sections were fixed in 4%
paraformaldehyde (Merck, Darmstadt, Germany). Staining
protocols were essentially as described [43]. Primary antibodies
were as follows: monoclonal rat anti-mouse PECAM-1 clone Mec
13.3 and 390 (BD, San Diego, CA), polyclonal rabbit anti-mouse
F4/80 (Serotec, Oxford, UK), monoclonal anti-mouse IA/I-E
(clone 2G9) FITC conjugated (BD), polyclonal rabbit anti-mouse
NG2 (Chemicon, Temecula, CA), mouse anti-a-smooth muscle
actin (clone 1A4) FITC-conjugated (Sigma), rat anti-reticular
fibroblast marker (Cederlane Laboratories, Ontario, Canada).
The following secondary antibodies were used: goat anti-rat
biotinylated or FITC conjugated and goat anti-rabbit Texas Red
conjugated (Vector laboratories, Burlingame, CA). For immuno-
histochemistry, biotinylated immune-complexes were detected by
the Vectastain ABC elite kit (Vector laboratories) with DAB as
substrate (Zymed laboratories; Carlsbad, CA). Mayers Hematox-
ylin (Histolab, Go ¨teborg, Sweden) and DAPI (Sigma) were used
as a counter stains for immunohistochemistry and immunofluo-
rescence respectively. Sections were analyzed with a Nikon
Labophot fluorescence microscope and images were retrieved
with a CCD camera and software from SPOT (Diagnostic
Instruments, Sterling Heights, MI). Image analysis and quanti-
fications was performed with Photoshop (Adobe, San Jose ´, CA)
and ImageJ (NIH, Bethesda, MD) software. For quantification of
pixels, at least 5 images (6200 magnification) per tumor (n=7 for
each genotype) for each type of staining were used. Quantifica-
tion of blood vessels in CT26 tumors grown in integrin b3-
deficient (n=9) and WT mice (n=6) was performed by
stereology as described earlier [44].
Hydroxyproline measurement
Hydroxyproline content was determined in CT26 tumor
hydrolysates from integrin b3-deficient and WT mice (n=4 for
each genotype) essentially as described [45].
RNA extraction and quantitative real time PCR (qRT-PCR)
Total RNA was extracted from CT26 tumors grown in integrin
b3-deficient (n=12) and WT mice (n=11) and from LM3 tumors
grown in integrin b3-deficient and WT mice (n=6 for each
genotype) with RNeasy Mini Kit (Qiagen, Valencia, CA)
according to the manufacturers’ instructions. RNA integrity was
verified with electrophoresis and 1 mg total RNA was subjected to
first strand cDNA synthesis with Superscript III First-Strand
Synthesis Supermix for qRT-PCR (Invitrogen). QRT-PCR for
each sample were performed on LightCycler (Roche Applied
Science) in duplicates or triplicates by mixing cDNA with
Maxima
TM SYBR Green qPCR Master Mix (Fermentas, St.
Leon-Rot, Germany) and gene specific primer pairs (available
upon request). Amplification results were analyzed using Light-
Cycler software Version 3. The calculated threshold cycle values
for each gene were normalized to the threshold cycle value of the
internal standard hypoxanthine phosphoribosyltransferase 1
(Hprt1). Relative gene expression levels are presented as fold
change in tumors grown in integrin b3-deficient mice normalized
to the gene expression levels in tumors from WT mice using the
2
2DDCt method [46].
Electron microscopy (EM)
Determinations of collagen fibril diameters were performed by
transmission EM analyses of tail tendons, dermis and Achilles
tendons from WT and integrin b3-deficient mice (n=2 for each
genotype); CT26 tumors (n=5 for each genotype); and LM3
tumors (n=3 for each genotype). Specimens were fixed in 0.15 M
sodium cacodylate-buffered 2% glutaraldehyde, postfixed in
0.15 M sodium cacodylate-buffered 1% osmium tetraoxide,
dehydrated in graded ethanol series, impregnated in acetone
and embedded in epoxy resin. Ultra-thin sections from at least
three different areas per sample were examined in a Philips CM-
10 electron microscope (Philips, Amsterdam, Netherlands) and
quantitated with ImageJ software (NIH). For scanning EM analysis
to investigate fiber structure, CT26 tumors (n=8 for each
genotype) and LM3 tumors (n=4 for each genotype) were
processed by alkali maceration as described [47] and analyzed
in a Philips 515 electron microscope.
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A SensolyteH 520 matrix metalloproteinase (MMP) assay
(Nordic Biosite, Stockholm, Sweden) was used according to the
manufacturer’s instructions. Briefly, CT26 tumors from WT and
integrin b3-deficient mice (n=6 for each genotype) were lysed
overnight in the included assay buffer supplemented with protease
inhibitors (Complete EDTA-free, Roche Applied Science) and
0.1% Triton X-100. The samples were homogenized by 20 strokes
with a Dounce homogenizer. After clarification by centrifugation
at 17,0006 g, samples were loaded onto a black 96-well plate
(Packard). Human recombinant MMP-13 (R&D Systems) was
included as a positive control. Recombinant MMP-13 and samples
were activated by 4-aminophenylmercuric acetate (APMA; Sigma)
for 40 min at 37uC. Cleavage of the substrate 5-FAM/
QXL
TM520 FRET peptide was measured in a Wallac Victor
1420 (Perkin Elmer, Waltham, MA).
Statistical analyses
All statistics were performed in GraphPad Prism Version 4.0
using Student’s t-test or Mann-Whitney test. Data is presented as
mean 6 standard error of the mean (SEM) if not otherwise
indicated. To analyze the total number of collagen fibrils counted,
the data points (diameter for each fibril) was tabulated in
GraphPad using the Frequency distribution analysis tool.
Supporting Information
Figure S1 End weights in CT26 and LM3 carcinomas. A)
The mean end weight of CT26 tumors from integrin b3-deficient
and WT mice was 15656719 mg and 13136529 mg (n=22 and
24, respectively; p.0.17). CT26 tumors were harvested 2465
days after tumor cell injection from integrin b3-deficient mice and
2366 days after tumor cell inoculation from WT mice (p.0.91).
Data was analyzed with Student’s t-test. Bars are SD. B) The
mean end weight of LM3 tumors from integrin b3-deficient and
WT mice was 5086206 mg and 4866165 mg (n=8 for each
genotype; p.0.79). LM3 tumors were harvested 2866 days after
tumor cell injection of integrin b3-deficient mice and 2864 days
after tumor cell inoculation of WT mice (p.0.78). Data was
analyzed with Mann-Whitney test. Bars are SD.
(TIF)
Figure S2 Average collagen fibril diameter in CT26 and
LM3 carcinomas and in tail dermis. Mean fibril diameter
was calculated for every tumor or tissue from at least three
micrographs per sample. A) Average fibril diameter in CT26
tumors were 79613 nm from integrin b3-deficient mice and
4462 nm from WT mice (n=5 for each genotype; p,0.03). B)
Average fibril diameter in LM3 tumors were 5662 nm from
integrin b3-deficient mice and 4762 nm from WT mice (n=3 for
each genotype; p,0.05). C) Average fibril diameter in tail dermis
were 8167 nm from integrin b3-deficient mice and 8166n m
from WT mice (n=2 for each genotype; p.0.98). Data was
analyzed with Student’s t-test. Error bars are SEM.
(TIF)
Figure S3 Quantitative RT-PCR analyses of mRNAs
encoding collagen and lysyl oxidase in LM3 tumors.
Relative mRNA expression of fibrillar pro-collagens and lysyl
oxidase (Lox) in LM3 tumors grown in integrin b3-deficient
(n=12) compared to WT mice (n=11). Bars indicate fold changes
in tumors grown in integrin b3-deficient mice after normalization
to tumors from WT mice using the 2
2DDCt method. Data was
analyzed with Student’s t-test. Error bars are SEM.
(TIF)
Figure S4 Quantitative RT-PCR analyses of mRNAs
encoding VEGF-receptor 2, TGF-b1 and TGF-b3, TGF-b-
receptor 2 and CTGF in CT26 tumors. Relative mRNA
expression of genes encoding VegfR2,TGF-b1, TGF-b3, TGFbR-
II and connective tissue growth factor (CTGF) in CT26
carcinomas from integrin b3-deficient (n=12) compared to WT
mice (n=11). Bars indicate fold changes in tumors grown in
integrin b3-deficient mice after normalization to tumors from WT
mice using the 2
2DDCt method. Data was analyzed with Student’s
t-test. Error bars are SEM.
(TIF)
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